Article
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Journal of gastroenterology and hepatology - 1 Jul 2002
Inaba Tomoki, Mizuno Motowo, Kawai Kozou, Yokota Kenji, Oguma Keiji, Miyoshi Masatsugu, Take Susumu, Okada Hiroyuki, Tsuji Takao
Abstract excerpt
BACKGROUND AND AIMS: Genetic polymorphism of cytochrome P450 (CYP) 2C19 influences the efficacy of Helicobacter pylori eradication therapy with a proton pump inhibitor (PPI) and amoxicillin. However, in triple therapy (PPI plus amoxicillin and clarithromycin), little is known about the impact of CYP2C19 polymorphism, or the use of rabeprazole, which is not well metabolized by CYP2C19. The efficacy of three PPI...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
